SEARCH

SEARCH BY CITATION

References

  • 1
    Dijkman GA & Debruyne FMJ. Epidemiology of prostate cancer. Eur Urol 1996; 30: 28195
  • 2
    Post PN, Kil PJM, Crommelin MA, Schapers RFM, Coebergh JWW. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in Southeastern Netherlands. 1971–95. Eur J Cancer 1998; 34: 7059DOI: 10.1016/s0959-8049(97)10154-x
  • 3
    Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 90723
  • 4
    Bishop MC, Hardy JG, Taylor MC, Wastie ML, Lemberger RJ. Bone imaging and serum phosphatases in prostatic carcinoma. Br J Urol 1985; 57: 31724
  • 5
    Chybowski FM, Larson Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 3138
  • 6
    Oesterling JE. Using PSA to eliminate the staging radio nuclide bone scan. Significant economic implications. Urol Clin North Am 1993; 20: 70511
  • 7
    Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992; (Suppl. 4): 12938
  • 8
    Mostofi FK, Sesterhenn IA, Sobin LH. Histological typing of prostate tumours. In International Histological Classification of Tumours, no. 22. Geneva: World Health Organization, 1980
  • 9
    Wymenga LFA, Groenier K, Visser-van Brummen P, Marrink J, Mensink HJA. Reliability analysis of first and second generation PSA assays. Can J Urol 2000; 7: 10706
  • 10
    Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol 1992; 70: 2958
  • 11
    Kemp PM, Maguire GA, Bird NJ. Which patients with prostatic carcinoma require a staging bone scan? Br J Urol 1997; 79: 6114
  • 12
    O'Mara RE. Skeletal scanning in neoplastic disease. Cancer 1976; 37: 4806
  • 13
    Terris MK, Klonecke AS, McDougall IR, Stamey TA. Utilization of bone scans in conjunction with prostate specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991; 32: 17137
  • 14
    Schaffer DL & Pendergrass HP. Comparison of enzyme, clinical, radiographic and radionuclide methods of detecting bone metastasis from carcinoma of the prostate. Radiology 1976; 121: 4314
  • 15
    Gerber G & Chodak GW. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology 1991; 37: 41822
  • 16
    Oesterling JE, Martin SK, Bergstrahl EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 5760
  • 17
    Lee CT & Oesterling JE. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 1997; 24: 38994
  • 18
    Rana A, Karamanis K, Lucal MG, Chisholm GD. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol 1992; 69: 27781
  • 19
    O'Donoghue JM, Rogers E, Grimes H et al. A reappraisal of serial isotope scans in prostate cancer. Br J Radiol 1993; 66: 6726
  • 20
    Oommen R, Geethanhali FS, Gopalakrishnan G et al. Correlation of serum prostate-specific antigen levels and bone scintigraphy in carcinoma prostate. Br J Radiol 1994; 67: 46971
  • 21
    Wolff JM, Bares R, Jung PK, Buell U, Jakse G. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int 1996; 56: 16973
  • 22
    Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998; 33: 37681

Authors

  1. Authors

L.F.A. Wymenga, MD, Urologist.

J.H.B. Boomsma, MD, PhD, Radiologist.

K. Groenier, MD, Epidemiologist.

D.A. Piers, MD, PhD, Nuclear Specialist.

H.J.A. Mensink, MD, PhD, Professor of Urology.

Abbreviations
ALP

alkaline phosphatase